Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4646 Monotherapy in ART-Naïve Participants With HIV-1
NCT07042945Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1 trial of MK-4646 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Merck & Co. Primary endpoints: Participants with adverse events, Participants who discontinued study medication due to an AE at 7 days and 1 more. Started Jul 2025; status: completed.
02
Drugs
MK-4646
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07042945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042945.